Table 1.
Patient characteristics and perioperative data
| Characteristics | All patients (N=15) |
|---|---|
| Age (years), mean (range) | 52.4 (36–74) |
| Gender, male: female | 9:6 |
| Neoadjuvant chemotherapy, n (%) | 9 (60) |
| Pre-CRS L-HIPEC, n (%) | 4 (26.7) |
| NIPS, n (%) | 1 (6.7) |
| PSS, n (%) | |
| 0 | 2 (13.3) |
| 1 | 9 (60.0) |
| 2 | 4 (26.7) |
| CEA (ng/mL), (normal 0–5 ng/mL), mean (range) | 21.2 (0.9–145.0) |
| CA19–9 (U/mL), (normal 0–37 U/mL), mean (range) | 23.3 (1.0–127.0) |
| CA125 (U/mL), (normal 0–35 U/mL), mean (range) | 70.8 (6.2–181.3) |
| Ascites, n (%) | 10 (66.7) |
| PCI, mean ± SD (range), median | |
| Preoperative | 23.1±12.9 (0–39), 26 |
| Postoperative | 16.6±14.2 (0–39), 18 |
| CC, n (%) | |
| 0 | 3 (20.0) |
| 1 | 1 (6.7) |
| 2 | 5 (33.3) |
| 3 | 6 (40.0) |
| HIPEC regimen, n (%) | |
| Nil | 4 (26.7) |
| MMC | 8 (53.3) |
| 5-FU + oxaliplatin | 3 (20.0) |
| Colostomy or ileostomy, n (%) | 5 (33.3) |
| EPIC, n (%) | 6 (40) |
| Operation time (minutes), mean (range) | 230 (170–375) |
| Blood loss (mL), mean (range) | 1098 (200–3000) |
| Morbidity, n (%) | |
| Grade 0 | 8 (53.3) |
| Grade 1–2 | 5 (33.3) |
| Grade 3–5 | 2 (13.4) |
| Admission days, median ± SD (range) | 28±53.0 (12–190) |
| Adjuvant chemotherapy, n (%) | 6 (40) |
Abbreviations: 5-FU, 5-fluorouracil; CC, completeness of cytoreduction; CEA, carcinoembryonic antigen; CRS, cytoreductive surgery; EPIC, early postoperative intraperitoneal chemotherapy; GCCs, goblet cell carcinomas; HIPEC, hyperthermic intraperitoneal chemotherapy; L-HIPEC, laparoscopic HIPEC; MMC, mitomycin C; NIPS, neoadjuvant intraperitoneal and systemic chemotherapy; PCI, peritoneal cancer index; PSS, prior surgical score.